Kurzfassung

A phase 1 / 2 , open-label, randomized study of the safety, efficacy, and pharmacokinetics of Letrozol plus PD 0332991 (Oral CDK 4 / 6 Inhibitor) and Letrozol singel agent for the first-line treatment of ER positve, HER2 negaitve advanced breast cancer in postmenopausal women.
Pfizer